- SAB Biotherapeutics Announces Departure of Chief Financial Officer
- FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
- SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
- SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
- SAB Biotherapeutics Provides SAB-142 Trial Update
- SAB Biotherapeutics to Present at INNODIA Annual Meeting
- SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
- SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
- SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
- SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
As of last trade, SAB Biotherapeutics Inc (SABS:NAQ) traded at 2.64, 11.86% above the 52 week low of 2.36 set on May 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.79 |
---|---|
High | 2.82 |
Low | 2.64 |
Bid | 2.59 |
Offer | 2.83 |
Previous close | 2.82 |
Average volume | 17.09k |
---|---|
Shares outstanding | 9.23m |
Free float | 7.46m |
P/E (TTM) | -- |
Market cap | 24.37m USD |
EPS (TTM) | -6.26 USD |
Data delayed at least 15 minutes, as of May 30 2024 21:00 BST.
More ▼